The British Association of Aesthetic Plastic Surgeons (BAAPS) has welcomed
the decision to withdraw a procedure which promised that patients could undergo
a breast augmentation in a short space of time.
It was promoted as the 'lunchtime boob job' and involved using the injectable
filler Macrolane, but concerns regarding the procedure exposing patients to an
increased threat of cancer mean it will not be available anymore.
A survey of BAAPS members found that one in four observed patient complications
resulting from the use of Macrolane near the breast tissue.
President of the group Fazel Fatah said: "Any treatment can only be
considered safe once it is known what long term effect it has on cancer
screening, as this can affect such a high proportion of women."
She added dermal fillers such as Macrolane should always be viewed with caution
until five to ten-year studies are available and they should be reclassified as
medicines.
© Adfero Ltd
Cosmetic surgery news : 25 April 2012
